DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer
DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer
The purpose of this study is to measure the efficacy and safety of T-DXd with rilvegostomig or T-DXd monotherapy compared with gemcitabine plus cisplatin and durvalumab in patients with advanced treatment naïve HER2-expressing BTC.
Key Inclusion Criteria:
Key Exclusion Criteria:
information.center@astrazeneca.com1-877-240-9479
Fukuyama-shi, 721-8511, Japan
Hirakata-shi, 573-1191, Japan
Kawasaki-shi, 216-8511, Japan
Kita-gun, 761-0793, Japan
Kitaadachi-gun, 362-0806, Japan
Mitaka-shi, 181-8611, Japan
Shinjuku-ku, 160-8582, Japan
Sunto-gun, 411-8777, Japan
Ube-shi, 755-8505, Japan
Hwasun-gun, 58128, South Korea
Muang, 50200, Thailand
Mueang, 47000, Thailand
Naimuang, 30000, Thailand
Greater London, SW3 6JJ, United Kingdom